Changes in the Structural and Functional Albumin Properties in Patients with Decompensated Liver Cirrhosis

Аim: to conduct a comparative analysis of serum albumin's structural and functional properties in decompensated cirrhotic patients by means of spin prob EPR spectroscopy.

Materials and methods. The main study group included 70 patients with decompensated liver cirrhosis and ascites. The control group consisted of 12 healthy volunteers, comparable in gender and age, without liver diseases. To assess the structural and functional ability, serum albumin was analyzed by EPR spectroscopy.

Results. Albumin levels within reference intervals were found in 37 patients (59.8 %). The native albumin index decrease in cirrhotic patients as the disease progressed with the lowest values in the Child – Pugh C group (p < 0.001). The binding efficiency of albumin decreased in accordance with the severity of cirrhosis with minimal albumin binding capacity in the Child – Pugh C (Me = 25.43 %; n = 30; p < 0.001). The transport activity of RTQ albumin decreased in patients with decompensated cirrhosis, the lowest transport ability was observed in the Child – Pugh C group (Me = 26.09 %). In patients with decompensated disease the detoxification potential was significantly reduced: Child – Pugh B — Me = 44.03 %; Child – Pugh C — Me =17.16 %. Despite the normal values of serum albumin in 72.5% of patients with cirrhosis B and in 26.7% in the cirrhosis C group, only 12.3% in the cirrhosis B group had normal albumin function and in cirrhosis C nо patients had normal albumin function.

Conclusion. There were not only serum concentration depletion in cirrhotic patients, but also albumin physiological non-oncotic properties were violated. The severity of these changes increased with the progression of cirrhosis. Our data allow us to raise the question of the need to use the EPR test to determine indications for albumin replacement therapy in patients with cirrhosis and the presence of ascites, even at normal values of its serum concentration.

1. Maevskaya M.V., Zharkova M.S. Role of human albumin in the management of liver cirrhosis. Meditsinskiy sovet = Medical Council. 2020;5:62–9 (In Russ.). DOI: 10.21518/2079-701X-2020-5-62-69

2. Karimia M., Bahramia S.B., Ravaric S.B., Zangabadd P.S., Mirshekarie H., Bozorgomidf M., et al. Albumin nanostructures as advanced drug delivery systems. Expert Opin Drug Deliv. 2016;13(11):1609–23. DOI: 10.1080/17425247.2016.1193149

3. Tufoni M., Baldassarre M., Zaccherini G., Antognoli A., Caraceni P. Hemodynamic and Systemic Effects of Albumin in Patients with Advanced Liver Disease. Curr Hepatol Rep. 2020;1–12. DOI: 10.1007/s11901-020-00521-1

4. Garcia-Martinez R., Caraceni P., Bernardi M., Gines P., Arroyo V., Jalan R. Albumin: pathophysiologic basis of its role in the treatment of cirrhosis and its complications. Hepatology. 2013;58:1836–46. DOI: 10.1002/hep.26338

5. Casulleras M., Alcaraz-Quiles J., Duran-Güell M., Flores-Costa R., Titos E, López-Vicario C., Horrillo R., et al. FRI-111-albumin modulates endosomal TLR9 signaling in human peripheral leukocytes: a mechanism for its anti-inflammatory role in ACLF. J Hepatol. 2019;70:e436. DOI: 10.1016/s0618-8278(19)30856-4

6. Naldi M., Baldassarre M., Domenicali M., Bartolini M., Caraceni P. Structural and functional integrity of human serum albumin: analytical approaches and clinical relevance in patients with liver cirrhosis. J Pharm Biomed Anal. 2017;144:138–53. DOI: 10.1016/j.jpba.2017.04.023

7. Zunszain P.A., Ghuman J., McDonagh A.F., Curry S. Crystallographic analysis of human serum albumin complexed with 4Z,15E-bilirubin-IXalpha. J Mol Biol. 2008;381(2):394–406. DOI: 10.1016/j.jmb.2008.06.016

8. Quinlan G.J., Martin G.S., Evans T.W. Albumin: biochemical properties and therapeutic potential. Hepatology. 2005;41:1211–9. DOI: 10.1002/hep.20720

9. Hayashi T., Suda K., Imai H., Era S. Simple and sensitive high-performance liquid chromatographic method for the investigation of dynamic changes in the redox state of rat serum albumin. J Chromatogr B Analyt Technol Biomed Life Sci. 2002;772(1):139–46. DOI: 10.1016/s1570-0232(02)00068-5

10. Lotosh N.Y., Savelyev S.V., Selishcheva A.A. Glycation of albumin in vitro at normal and elevated glucose concentrations. Pathogenesis. 2015;13(2):42–6

11. Baldassarre M., Domenicali M., Naldi M., Laggetta M., Giannone F.A., Biselli M., et al. Albumin homodimers in patients with cirrhosis: clinical and prognostic relevance of a novel identified structural alteration of the molecule. Sci Rep. 2016;6:35987. DOI: 10.1038/srep35987

12. Domenicali M., Baldassarre M., Giannone F.A., Naldi M., Mastroroberto M., Biselli M., et al. Posttranscriptional changes of serum albumin: clinical and prognostic significance in hospitalized patients with cirrhosis. Hepatology. 2014;60(6):1851–60. DOI: 10.1002/hep.27322

13. Baldassarre M., Naldi M., Zaccherini G., Bartoletti M., Antognoli A., Laggetta M., et al. Determination of Effective Albumin in Patients With Decompensated Cirrhosis: Clinical and Prognostic Implications. Hepatology. 2021;74(4):2058–73. DOI: 10.1002/hep.31798

14. Gligorijević N., Minić S., Nedić O. Structural changes of proteins in liver cirrhosis and consequential changes in their function. World J Gastroenterol. 2022;28(29):3780–92. DOI: 10.3748/wjg.v28.i29.3780